AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia
Phase 3
Completed
- Conditions
- Hyperkalemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (ZS) 5gDrug: Sodium Zirconium Cyclosilicate (ZS) 10gDrug: Placebo
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 267
- Registration Number
- NCT02875834
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 233
- Registration Number
- NCT02869438
- Locations
- 🇵🇭
Research Site, Quezon City, Philippines
Adherence Study in COPD Patients
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT02864342
- Locations
- 🇺🇸
Research Site, Spartanburg, South Carolina, United States
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
Phase 1
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: Epanova™ QD (2 x 1 g capsules)Drug: Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg doseDrug: Multiple (20) oral doses of 2 g Vascepa® every 12 hours
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 114
- Registration Number
- NCT02859129
- Locations
- 🇺🇸
Celerion, Neptune, New Jersey, United States
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
Completed
- Conditions
- Diabetes Mellitus Type 2
- First Posted Date
- 2016-07-25
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15498
- Registration Number
- NCT02843399
- Locations
- 🇺🇸
Research site, Wilmington, Delaware, United States
Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now
Terminated
- Conditions
- Non-Small-Cell Lung Cancer
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23
- Registration Number
- NCT02835599
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT02826525
Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: BenralizumabOther: Placebo
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT02821416
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT02814656
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 103
- Registration Number
- NCT02814643
- Locations
- 🇺🇸
Research Site, Clinton, Utah, United States